Hg 1) . For transcriptome analysis, total RNAs from whole peripheral blood cells were extracted with using PAXgene miRNA kit. After constructing single-stranded, strand-specific libraries, multiplex sequencing was done. After quantifying the expressions of transcripts, differentially expressed genes (DEGs) between exPH and exN group were selected by paired T-test (P<0.05). And then, hierarchical clustering analysis and pathway enrichment analysis (PathVisio) were performed. Results: There were no significant differences between exPH and exN group in the result of total skin score, serum BNP, tests of pulmonary function and thermography after 0°C-stress. Positive SSc-related autoantibody was a risk factor for exPH (odds ratio, 1.41); especially, positive anti-RNP seemed to be prominent (odds ratio, 3.21). Based on the 817 DEGs between exPH and exN group, the hierarchical clustering showed major 4 clusters, and one of them consisted of only cases in exPH group. When we focused on 117 genes reported to be directly implicated in the development of PAH 2) , it is noteworthy that 4 of them including TGF-β induced protein were differentially expressed. Pathway analysis of transcriptome revealed that 22 pathways, such as hypertrophy model, lung fibrosis and Wnt/B-catenin signaling, were differently enriched between exPH and exN group. Conclusions: The paradigm of SSc-PAH management should ideally be aimed at detecting early PVD and starting treatment prior to fulfilling the criteria for PAH. Although detection of early PVD in SSc patients remains a major challenge, exercise DE seemed to be a good, non-invasive method for screening. It is noteworthy that expression changes in some of known PAH-related genes were detected from peripheral blood of exPH patients. It shows the possibility that the therapeutic intervention at early stage of the disease may alter the clinical course. 
FRI0418 FACTORS ASSOCIATED WITH STEROID-FREE REMISSION IN PATIENTS WITH INFLAMMATORY MYOPATHIES. A RETROSPECTIVE ANALYSIS OF A SINGLE-CENTER COHORT

Background:
The inflammatory myopathies are a heterogeneous group of connective tissue diseases characterized by muscle weakness and inflammation. Corticosteroids are the standard main treatment for inflammatory myopathies. However, steroid therapy often causes a wide range of side effects. Although immunosuppressive drugs are used as steroid-sparing agents in an effort to prevent disease recurrence, the appropriate duration of steroid use remains unclear. Objectives: We investigated whether steroid therapy can be safely withdrawn in patients with inflammatory myopathies followed in a single center. Methods: We retrospectively reviewed clinical charts of 71 consecutive patients (age 51.9±15.7 y.o., female 69%) who met Bohan and Peter criteria for polymyositis (PM)/dermatomyositis (DM) and modified Sontheimer's criteria for clinically amyopathic dermatomyositis (ADM), respectively. Steroid free remission was defined as a 3-month consecutive period of no disease activity without corticosteroid treatment. Factors associated with steroid free remission were examined. Results: Of 71 identified patients, 29 patients (40%) were DM, 15 patients (21%) were PM, 9 patients (13%) were overlap myositis, and 18 patients (25%) were ADM. Thirty-seven patients (52%) had muscle weakness, 5 patients (7%) had malignancies and 43 patients (61%) had signs of interstitial lung disease. With a mean follow-up of 6.6±5.0 years, 9 patients (13%) died during follow-up period. The remaining 62 patients were treated with corticosteroids alone or in combination with immunosuppressants. Steroid-free remission was achieved in 21 of 62 patients (34%) patients with a mean time to steroid withdrawal of 5.5±4.0 years. Six of 21 patients (29%) relapsed 1.7±1.7 years after steroid withdrawal. There were no differences in onset of age, disease duration, positive ANA, positive Anti Jo-1 antibodies, serum creatine kinase levels, maximum dose of corticosteroids, skin, joint and lung involvement between steroid-free group and non-steroid-free group. Elevated inflammatiory markers were associated with long-term steroid use (p=0.038). Concominant immunosuppressants were more frequently used in non-steroid-free group than steroid-free group (p=0.002). Conclusions: Steroid-free remission might be achieved in some patients with inflammatory myopathies. Background: Interstitial lung disease (ILD) and concomitant infectious diseases are the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that hypocapnea and ILD lesion in upper lung fields are independent prognostic factors. Micro RNA is a non-coding RNA, which has a certain function such as transcriptional regulation. miR-1 has been reported to be associated with myocyte differentiation and to decrease in muscle tissue from patients with inflammatory myopathies. Objectives: Here we investigated the association of serum miR-1 level with clinical course of PM/DM-associated ILD (PM/DM-ILD). Methods: We retrospectively analyzed clinical baseline, serum miR-1 level, initial therapeutic regimens, total amounts of PSL, clinical outcomes, and episode of infection of patient with PM/DM-ILD who had received initial treatment at six hospitals associated with Yokohama City University from 2003 to 2016. The serum miR-1 level was measured by quantitative real-time PCR. Results: One hundred sixteen (PM 22, DM 51, and clinically amyopathic DM 43) patients were included. The mean age was 56±15 years and 83 were female. As initial therapies, oral PSL, methylprednisolone (mPSL) pulse, intravenous cyclophosphamide (IVCY), and oral calcineurin inhibitor therapies were performed in 113 (97%), 80 (69%), 48 (41%) and 80 (69%), respectively. Forty-one patients had a serious infection at 51±38 days from initiation of immunosuppressants and 10 died of infections. Old age, low PaCO 2 and albumin, high LDH and KL-6, high score of ILD, high initial dose of PSL, mPSL pulse, IVCY, calcineurin inhibitor and combination therapy were extracted as risk factors for infection by univariate analyses. A multivariate logistic regression analyses revealed that combination therapy (p=0.012, OR 2.83), old age (p=0.024, OR 2.12), high initial dose of PSL (p=0.024, OR 2.69), low albumin (p=0.031, OR 3.56), and low PaCO 2 (p=0.038, OR 2.67) were independent risk factors for infection. Serum samples were obtained from total of 14 patients and 13 healthy controls. Serum miR-1 levels in PM/DM-ILD patients before treatment were significantly higher than those in healthy controls (p=0.047). Also serum miR-1 levels were significantly higher in PM/DM-ILD patients with concomitant infectious diseases as compared to patients without infectious diseases (p=0.043). We further divided the PM/DM-ILD cases into two groups by the serum miR-1 level. The higher miR-1 group showed poorer effectiveness of ILD treatment (p=0.040), and lower lymphocyte count (p=0.013) as compared to the lower miR-1 group. Conclusions: Appropriate monitoring is important for PM/DM-ILD, especially in older patients with malnutrition or decreased respiratory function. miR-1 can be a new biomarker for predicting treatment response and concomitant infectious diseases during treatment for PM/DM-ILD. 
